Investigation of the effect of Zufa syrup on clinical symptoms in the with suspected Corona (COVID-19)

Investigation of the effect of Zufa syrup on clinical symptoms in the with suspected Corona(COVID-19)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200404046934N1

Enrollment

130

Registered

2020-04-13

Start date

2020-03-10

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus. Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention 1: Intervention group: under treatment with Zufa syrup 6 times a day (every 4 hours) and 7.5 cc each time for 10 days made by Bouali Daru Pharmaceutical Company. Intervention 2: Control

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age between 20-70 Lung tissue involvement due to CT scan Need for medication prescribes Coronavirus treatment Patients who are treated at home.

Exclusion criteria

Exclusion criteria: Heart, lung, liver and kidney disease Blood pressure above 160 mm Hg Fever above 39. C Diabetic patients Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
Clinical signs Includes oxygen saturation, temperature, blood pressure, respiration rate, heart rate. Timepoint: During 10 days of treatment and 5 days after treatment. Method of measurement: Individual profile and follow-up questionnaire.;Oxygen levels. Timepoint: During 10 days of treatment and 5 days after treatment. Method of measurement: Oximeter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRazieh Borujerdi

Ghoum University of Medical Sciences

borujerdi.teb@gmail.com+98 25 3612 2058

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 12, 2026